THE DEFINITIVE GUIDE TO ONO-8713

murine design. Therefore, derivatives of SU9516 with reduced toxicity are warranted for medical trials. This study leads the best way for additional development of smaller-molecule therapeutics targeting the αsevenβone integrin advanced in DMD.In contrast, the compound exhibited non-competitive inhibition with regard to ATP toward cdk4/cyclin D1,